Papers
10
Total Citations
594
H-Index
6
About
Eitan Prisman is a leading head and neck surgical oncologist whose work has fundamentally shaped the treatment of oropharyngeal squamous cell carcinoma (OPSCC), particularly through the landmark ORATOR clinical trials. As the principal investigator of the ORATOR program, he led the first randomized comparison of radiotherapy versus transoral robotic surgery (TORS) for early-stage OPSCC—a study that has garnered over 458 citations and directly informs clinical decision-making worldwide. His research focuses on optimizing surgical outcomes, reducing treatment morbidity, and improving quality of life for patients with HPV-related oropharyngeal cancers. Dr. Prisman has made seminal contributions in understanding readmission patterns after TORS (32 citations), the role of pathologic muscle invasion in prognostication, and decisional regret following surgery. He is also pioneering novel intraoperative imaging techniques, including transcervical ultrasound guidance and MRI-ultrasound registration for TORS, aiming to improve resection margins and reduce recurrence. His work on ectopic lingual thyroid excision (31 citations) further demonstrates his expertise in minimally invasive robotic approaches. With over 590 total citations, Dr. Prisman continues to advance the field through rigorous clinical trials and translational innovation, establishing evidence-based standards for the surgical management of head and neck cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8Towards transcervical ultrasound-guided transoral robotic surgery4 citations · 2025
- 9
- 10